Copper, Zinc Acetate, and Lactide Intravaginal Ring
CZL-IVR
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal Ring
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Population Council, Queen's University Belfast, Weill Cornell Medical College
Details
- API: Copper, Zinc Acetate, Lactide
- Target: Progesterone Receptor
-
Mechanism of Action:
- Inhibition of Sperm Capacitation
- Inhibition of Sperm Motility
- Anti-Microbial
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Potential MPT
- Promising Attributes: The method offers both pregnancy prevention and prevention of STIs (herpes simplex virus, gonorrhea, chlamydia, and possibly HIV) while promoting vaginal health.
Product Status
Active Pre-Clinical Research
History
Since 2021, the Population Council and partners have received NIH funding to complete preclinical testing for a novel MPT containing CSA, ZLA, and lactide to determine the target API release and the overall safety and efficacy of the product. Separate funding is granted to support evaluation of end-user perspectives on the product profile. At the 2023 National Contraception Meeting, researchers from Queen's University Belfast shared formulation and testing updates for the CZL-IVR. Funding is active as of 2026.